| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |